These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 9363992

  • 1. Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
    Hattori K, Okamoto M, Oyasu R.
    Carcinogenesis; 1997 Oct; 18(10):1867-70. PubMed ID: 9363992
    [Abstract] [Full Text] [Related]

  • 2. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
    Okamoto M, Oyasu R.
    Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
    [Abstract] [Full Text] [Related]

  • 3. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells.
    Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK, Sun L, Brattain MG.
    J Biol Chem; 1996 Jul 19; 271(29):17366-71. PubMed ID: 8663343
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells.
    Turco A, Coppa A, Aloe S, Baccheschi G, Morrone S, Zupi G, Colletta G.
    Int J Cancer; 1999 Jan 05; 80(1):85-91. PubMed ID: 9935236
    [Abstract] [Full Text] [Related]

  • 5. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
    Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S, Yoshino G.
    Horm Metab Res; 2006 Mar 05; 38(3):159-66. PubMed ID: 16673206
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Overexpression of a dominant-negative type II TGFbeta receptor tagged with green fluorescent protein inhibits the effects of TGFbeta on cell growth and gene expression of mouse adrenal tumor cell line Y-1 and enhances cell tumorigenicity.
    Le Roy C, Maisnier-Patin K, Leduque P, Li JY, Saez JM, Langlois D.
    Mol Cell Endocrinol; 1999 Dec 20; 158(1-2):87-98. PubMed ID: 10630409
    [Abstract] [Full Text] [Related]

  • 10. Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma.
    Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Oyasu R.
    Int J Cancer; 1995 Nov 27; 63(5):680-7. PubMed ID: 7591285
    [Abstract] [Full Text] [Related]

  • 11. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
    Ananth S, Knebelmann B, Grüning W, Dhanabal M, Walz G, Stillman IE, Sukhatme VP.
    Cancer Res; 1999 May 01; 59(9):2210-6. PubMed ID: 10232610
    [Abstract] [Full Text] [Related]

  • 12. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
    Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JK.
    Cancer Res; 1999 Sep 15; 59(18):4725-31. PubMed ID: 10493532
    [Abstract] [Full Text] [Related]

  • 13. A new in vivo model for studying invasion and metastasis of rat and human bladder carcinomas.
    Kameyama S, Kawamata H, Kawai K, Oyasu R.
    Carcinogenesis; 1993 Aug 15; 14(8):1531-5. PubMed ID: 8353837
    [Abstract] [Full Text] [Related]

  • 14. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
    Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L.
    Cancer Res; 1999 Oct 01; 59(19):5041-6. PubMed ID: 10519421
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antisense RNA-mediated reduction of p53 induces malignant phenotype in nontumorigenic rat urothelial cells.
    Okamoto M, Hattori K, Fujimoto K, Tanaka Y, Gloosby CL, Oyasu R.
    Carcinogenesis; 1998 Jan 01; 19(1):73-9. PubMed ID: 9472696
    [Abstract] [Full Text] [Related]

  • 17. Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells.
    Chen C, Wang XF, Sun L.
    J Biol Chem; 1997 May 09; 272(19):12862-7. PubMed ID: 9139748
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo acceleration of the neoplastic phenotype of a low-tumorigenicity rat bladder carcinoma cell line by transfected transforming growth factor-alpha.
    Kawamata H, Kameyama S, Oyasu R.
    Mol Carcinog; 1994 Apr 09; 9(4):210-9. PubMed ID: 8148054
    [Abstract] [Full Text] [Related]

  • 19. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
    Clin Cancer Res; 2005 Jun 15; 11(12):4512-20. PubMed ID: 15958637
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma.
    Gleave ME, Hsieh JT, Wu HC, Hong SJ, Zhau HE, Guthrie PD, Chung LW.
    Cancer Res; 1993 Nov 01; 53(21):5300-7. PubMed ID: 8221665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.